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ABSTRACT 
Aim: To investigate anti-epileptic drug (AED) related weight changes in patients with 
epilepsy using a retrospective observational study. 
Method: We analysed the anonymised electronic primary care records of 1.1 million adult 
patients in Wales. We included adult patients with a diagnosis of epilepsy, whose body 
weight had been measured up to 12 months before starting, and between 3 and 12 months 
after starting one of five AEDs. We calculated the weight difference after starting the AED 
for each patient. 
Results: 1 423 patients were identified in total. The mean difference between body weight 
after and before starting each AED (together with 95% confidence intervals and p-values for 
no difference) were: carbamazepine 0.43 (-0.19, 1.05) p=0.17; lamotrigine 0.31 (-0.38, 1.00) 
p=0.38; levetiracetam 1.00 (0.16, 1.84) p=0.02; sodium valproate 0.74 (0.10, 1.38) p=0.02; 
topiramate -2.30 (-4.27, -0.33) p=0.02 
Conclusions: Levetiracetam and sodium valproate were associated with significant weight 
gain, topiramate was associated with significant weight loss, and lamotrigine and 
carbamazepine were not associated with significant weight change. 
INTRODUCTION 
Around 600 000 people (approximately 1% of the UK population) have a diagnosis of 
epilepsy and are prescribed anti-epileptic drugs (AEDs).[1] Most of these people will need 
lifelong treatment with AEDs. It is important for clinicians to have an accurate 
understanding of the side effect profile of AEDs in order to select the most suitable AED and 
be able to provide appropriate information to the patient. Both clinicians and patients 
identify AED side effects as a priority area of research in epilepsy.[2] 
There are several reasons why patients with epilepsy may experience weight change, one of 
these being AED therapy.[3] Weight gain is associated with an increased risk of co-
morbidities (e.g. hypertension, type 2 diabetes mellitus, heart disease and some types of 
cancer) and impairs quality of life and self-esteem. Weight loss is also associated with co-
morbidity (e.g. osteoporosis, immune and metabolic problems) - of particular importance in 
the young and elderly populations. Several AEDs have previously been linked to both weight 
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gain and weight loss.[3] If the risks of weight change are not adequately explained to 
patients then: they may lose the opportunity to ameliorate the risk via prospectively 
monitoring their weight and executing early lifestyle change; subsequent weight change 
may contribute to discontinuation of the associated AED with the associated risk of 
increased seizure frequency or the physician may risk stopping another medication not 
implicated in weight change by failing to identify the most likely drug. 
Most of the limited literature currently available on weight change and AEDs is derived from 
data from clinical trials. Our aim was to investigate and quantify weight change associated 
with five of the most commonly prescribed AEDs in the UK in a primary care setting. Having 
been routinely collected in the community, these prospectively acquired data are free from 
pharmaceutical industry bias. 
METHOD 
General practice (GP) electronic health records are stored at the health information 
research unit (HIRU) at Swansea University as part of the secure anonymised information 
linkage (SAIL) system.[4,5] At the time of analysis, approximately 40% of the Welsh 
population’s GP records were available on the SAIL system (around 1.1 million people).  
We electronically searched all SAIL records for adult patients with a coded diagnosis of 
epilepsy (Read code F25). We then refined our search by including only those people who: 
• had their weight recorded up to 12 months before starting one of five AEDs 
[carbamazepine (CBZ);  lamotrigine (LTG);  levetiracetam (LEV);  sodium valproate 
(VPA) and topiramate (TPM)] for the first time as monotherapy and  
• had their weight recorded within 3 to 12 months of starting and remaining on the 
same AED and 
• were 18 years of age or older at the time of starting the AED. (Significant weight gain 
can occur during various stages of child development and so children were not 
included in this study).   
We considered that most weight change associated with AED treatment occurs during the 
first 3 months after initiation,[6] and most people have reached an initial target dose in this 
period and so we chose a time window of 3–12 months after starting the AED for the second 
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weight measurement. We included generic and all recognised trade names for AEDs in the 
search. We excluded people who had a biologically implausible change (>40% of their 
baseline body weight) weight gain or loss within the study period. 
For each patient meeting the above criteria, we recorded age, sex, weight before starting 
the AED and weight after starting the AED. We recorded whether each patient was on AED 
monotherapy, was co-prescribed a common drug which may affect weight (corticosteroids, 
hypoglycaemic agents, antidepressants or antipsychotics) or had a common comorbidity 
which may affect weight (diabetes, thyroid disease, depression, psychosis). We then 
calculated the time between the weight measurements and the weight difference (the 
difference between the weights measured before and after starting the AED) for each 
person. We checked that the distribution of the absolute and relative weight changes were 
approximately normally distributed by plotting frequency and normal plots. Using paired t-
tests, we calculated the significance levels and confidence limits for the mean weight 
difference and mean percentage weight difference for each drug group. We used χ2 tests to 
compare the proportions of each group on AED monotherapy, co-prescribed common drugs 
which may cause weight change or with common potentially weight changing co-
morbidities.  
This project was approved by the HIRU information governance panel (project 0193). The 
National Research Ethics Service (NRES) has confirmed that projects using the anonymised 
data held by HIRU do not need specific NHS research ethics committee approval. 
RESULTS  
We identified 19 622 adult patients with a diagnosis of epilepsy (approximately 1.5% of the 
population covered by the SAIL database). Of these, 1 423 patients met our inclusion 
criteria. These patients had their weights recorded between the 18/11/1988 and 
04/04/2011. Table 1 and figure 1 gives the main results. 
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Drug n % 
male 
Age / 
years  
± 1 s.d. 
Mean 
weight 
before / 
kg ± 1 s.d. 
% on AED 
monotherapy 
(95% c.i.)a 
% on other 
medication 
potentially 
causing 
weight 
change  
(95% c.i.)b  
% with co-
morbidities 
potentially 
causing 
weight change  
(95% c.i)b 
Mean weight 
change  
/ kg (95% c.i.) p-
valuec 
Mean % weight 
change 
(95% c.i.) p-valuec 
CBZ 362 47 50.3  
± 18.1 
79.2  
± 19.5 
61.4 
(56.4,66.3) 
20.1 
(16.0,24.2) 
20.9 
(16.8,25.0) 
0.43  
(-0.19,1.05)  
p=0.17 
0.74  
(-0.07,1.55) 
p=0.07 
LTG 297 34 44.3  
± 18.8 
76.6  
± 19.8 
79.8 
(75.3,84.2) 
18.3 
(14.0,22.6) 
19.9 
(15.5,24.2) 
0.31  
(-0.38, 1.00) 
p=0.38 
0.50  
(-0.41, 1.41) 
p=0.28 
LEV 201 42 45.2  
± 16.3 
80.3  
± 21.8 
76.3 
(70.6,82.0) 
15.6 
(10.7,20.5) 
17.1 
(12.0,22.1) 
1.00  
(0.16, 1.84)  
p=0.02 
1.61  
(0.44, 2.78) 
p=0.007 
VPA 496 50 50.7  
± 19.7  
78.7  
± 20.4 
72.4 
(68.6,76.2) 
17.9 
(14.6,21.2) 
21.0 
(17.7,24.6) 
0.74 
 (0.10, 1.38)  
p=0.02 
1.21  
(0.41, 2.01) 
p=0.003 
TPM 67 27 40.4  
± 13.2 
86.5  
± 24.8 
65.7 
(54.5,76.8) 
17.1 (8.3, 
26.0) 
17.1 
(8.3,26.0) 
-2.30  
(-4.27, -0.33) 
p=0.02 
-2.62  
(-4.60, -0.64) 
p=0.01 
Table 1 : Results (CBZ = carbamazepine; LTG = lamotrigine; LEV = levetiracetam; VPA = sodium valproate; TPM = 
topiramate; s.d. = standard deviation; c.i. = confidence interval) ap-value <0.05 using χ2 test (4 dof), null hypothesis no 
difference between groups b p-value >0.05 using χ2 test (4 dof), null hypothesis no difference between groups ; cp-value 
using paired t-test and the null hypothesis of no weight change) 
<< Insert Figure 1 here >> 
Although broadly similar, there were some differences between groups in terms of patient 
demographics. There were significantly fewer patients in the topiramate group (n=67) 
compared with the other patient groups. Each patient group had 50% or more women, with 
LTG (66%) and TPM (73%) in particular having the highest proportion of women. The CBZ 
and VPA groups had a slightly older mean age in years (± 1sd) of 50.3 (± 18.1) and 50.7 (± 
19.7). The TPM group had a younger mean age of 40.4 (± 13.2). The time between the 
weight measurements was similar for all drug groups. The mean time in days between the 
first weight measurement and starting the AED was CBZ 119; LTG 119; LEV 127; VPA 125 and 
TPM 119. The mean time in days between the second weight measurement and starting the 
AED was CBZ 208; LTG 200; LEV 193; VPA 211 and TPM 203. 
Excessive weight changes are more important for the individual and can lead to 
discontinuing AED therapy. The proportion of people with a weight gain of > 10% (95% c.i.) 
for each drug group were CBZ 7.5% (4.6%, 10.3%); LTG 6.0% (3.2%, 8.9%); LEV 10.0% (5.6, 
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14.3); VPA 11.9% (8.9, 14.8) and TPM 4.5% (0, 10.2%). The proportion of people with a 
weight loss of > 10% (95% c.i.) for each drug group were CBZ 7.7% (4.8%, 10.6%); LTG 3.7% 
(1.4%, 6.0%); LEV 4.0% (1.0%, 6.9%); VPA 5.8% (3.7%, 8.0%); TPM 13.4% (4.5%, 22.3%). 
DISCUSSION 
Our data show that patients taking topiramate had a significant absolute and relative weight 
loss and that the levetiracetam and sodium valproate groups had significant absolute and 
relative mean weight gain. Patients taking carbamazepine and lamotrigine had non-
significant absolute and relative mean weight gain. We believe that this is the first study to 
demonstrate significant weight gain with levetiracetam. 
There was no significant difference between the groups in terms of the proportion of 
patients losing or gaining more than 10% of their baseline weight, or co-prescribed common 
drugs and common comorbidities known to cause weight change. The carbamazepine group 
had a significantly lower number of people on AED monotherapy when compared with the 
lamotrigine, levetiracetam and sodium valproate groups.   
There are inherent biases with this retrospective observational study. In particular, only 
patients who had their weight measured during a GP consultation within the appropriate 
time period were included. Patients who did not visit their GP or visited their GP but did not 
get their weight recorded were not included. However, this bias applies equally to each drug 
group in this study. The demographics of each group are also slightly different and may 
account for some of the differences in weight change between the groups; however this 
would not explain the difference in weight changes between the lamotrigine and 
levetiracetam group who are not significantly different in terms of age, sex or baseline 
weight.  
Previous data, largely from clinical trials, have associated weight gain with sodium 
valproate[3,7] and weight loss with topiramate.[8] Lamotrigine is generally considered to be 
weight neutral.[9] Both weight gain[10,11] and weight neutrality[12] has been associated 
with carbamazepine.  
A study by Gidal et al using pooled data from four clinical trials showed that levetiracetam 
did not cause weight gain[13]. It is not entirely clear why this finding is not replicated in our 
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study although the patients in the Gidel et al study were monitored regularly as part of 
clinical trials as opposed to being followed up in the community and were already 
established on one or two AEDs before starting levetiracetam (76% of our patients were on 
levetiracetam monotherapy). 
There are several mechanisms which may explain how sodium valproate causes weight gain, 
these include dysregulation of hypothalamic weight regulation mechanisms; altered 
adipokine (adipose tissue cytokine) transmission and altered insulin secretion / 
resistance.[6] Levetiracetam has a different mode of action than sodium valproate and the 
function of its main molecular target, synaptic vesicle protein 2A (SV2A) is largely 
unknown,[16] however, it may have a role in similar weight changing pathways. 
Topiramate is not normally used as a first line treatment for epilepsy – it is therefore less 
commonly prescribed than other AEDs explaining the fewer patients in the topiramate 
group. Epilepsy is considered to be slightly more common in males than females.[14] The 
larger number of female patients in this study may be explained by the fact that women are 
more likely to visit their general practitioner,[15] and may be more likely to consult about 
weight changes than men. Sodium valproate and carbamazepine are the oldest drugs in the 
group reflected in the slightly older mean age of the patients taking these drugs.  
In conclusion, when patients with epilepsy are observed in a primary care setting, certain 
antiepileptic drugs are associated with weight change. Levetiracetam and sodium valproate 
are associated with significant weight gain, topiramate with significant weight loss. 
Carbamazepine and lamotrigine are not associated with significant weight gain. We believe 
that this is the first time that levetiracetam has been associated with weight gain in a cohort 
of patients. Patients and clinicians need to be aware of the potential for weight change 
when starting AED therapy. 
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